Yield Optimisation of Hepatitis B Virus Core Particles in E. Coli Expression System for Drug Delivery Applications

Overview

Journal Sci Rep

Specialty Science

Date 2017 Mar 4

PMID 28256592

Citations 8

Authors

Izzat Fahimuddin Bin Mohamed Suffian

Mitla Garcia-Maya

Paul Brown

Tam Bui

Yuya Nishimura

Amir Rafiq Bin Mohammad Johari Palermo

Chiaki Ogino

Akihiko Kondo

Khuloud T Al-Jamal

Affiliations

Soon will be listed here.

Abstract

An E. coli expression system offers a mean for rapid, high yield and economical production of Hepatitis B Virus core (HBc) particles. However, high-level production of HBc particles in bacteria is demanding and optimisation of HBc particle yield from E. coli is required to improve laboratory-scale productivity for further drug delivery applications. Production steps involve bacterial culture, protein isolation, denaturation, purification and finally protein assembly. In this study, we describe a modified E. coli based method for purifying HBc particles and compare the results with those obtained using a conventional purification method. HBc particle morphology was confirmed by Atomic Force Microscopy (AFM). Protein specificity and secondary structure were confirmed by Western Blot and Circular Dichroism (CD), respectively. The modified method produced ~3-fold higher yield and greater purity of wild type HBc particles than the conventional method. Our results demonstrated that the modified method produce a better yield and purity of HBc particles in an E. coli-expression system, which are fully characterised and suitable to be used for drug delivery applications.

Citing Articles

A cell-penetrating bispecific antibody suppresses hepatitis B virus replication and secretion.

Xie C, Zhou B, Yao D, Wang X, Zhong L, Zhou L Virus Res. 2025; 353:199531.

PMID: 39863173 PMC: 11841211. DOI: 10.1016/j.virusres.2025.199531.

Size-selective downstream processing of virus particles and non-enveloped virus-like particles.

Hillebrandt N, Hubbuch J Front Bioeng Biotechnol. 2023; 11:1192050.

PMID: 37304136 PMC: 10248422. DOI: 10.3389/fbioe.2023.1192050.

Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.

Sazegari S, Akbarzadeh Niaki M, Afsharifar A, Niazi A, Derakhshandeh A, Moradi Vahdat M Microb Cell Fact. 2023; 22(1):39.

PMID: 36841778 PMC: 9958315. DOI: 10.1186/s12934-023-02043-z.

Rapid screening and scaled manufacture of immunogenic virus-like particles in a tobacco BY-2 cell-free protein synthesis system.

Armero-Gimenez J, Wilbers R, Schots A, Williams C, Finnern R Front Immunol. 2023; 14:1088852.

PMID: 36776898 PMC: 9909599. DOI: 10.3389/fimmu.2023.1088852.

Effects of Different Lengths of a Nucleic Acid Binding Region and Bound Nucleic Acids on the Phase Behavior and Purification Process of HBcAg Virus-Like Particles.

Valentic A, Muller J, Hubbuch J Front Bioeng Biotechnol. 2022; 10:929243.

PMID: 35845397 PMC: 9283707. DOI: 10.3389/fbioe.2022.929243.

References

Makrides S . Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol Rev. 1996; 60(3):512-38. PMC: 239455. DOI: 10.1128/mr.60.3.512-538.1996. View

Garcea R, Gissmann L . Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol. 2004; 15(6):513-7. DOI: 10.1016/j.copbio.2004.10.002. View

Jana S, Deb J . Strategies for efficient production of heterologous proteins in Escherichia coli. Appl Microbiol Biotechnol. 2005; 67(3):289-98. DOI: 10.1007/s00253-004-1814-0. View

Beterams G, Bottcher B, Nassal M . Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. FEBS Lett. 2000; 481(2):169-76. DOI: 10.1016/s0014-5793(00)01927-x. View

Sivashanmugam A, Murray V, Cui C, Zhang Y, Wang J, Li Q . Practical protocols for production of very high yields of recombinant proteins using Escherichia coli. Protein Sci. 2009; 18(5):936-48. PMC: 2771296. DOI: 10.1002/pro.102. View

Anderson R, Schneider J . Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine. 2007; 25 Suppl 2:B24-34. DOI: 10.1016/j.vaccine.2007.05.030. View

Greenfield N . Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2007; 1(6):2876-90. PMC: 2728378. DOI: 10.1038/nprot.2006.202. View

Lewellyn E, Loeb D . The arginine clusters of the carboxy-terminal domain of the core protein of hepatitis B virus make pleiotropic contributions to genome replication. J Virol. 2010; 85(3):1298-309. PMC: 3020508. DOI: 10.1128/JVI.01957-10. View

Pumpens P, Grens E . HBV core particles as a carrier for B cell/T cell epitopes. Intervirology. 2001; 44(2-3):98-114. DOI: 10.1159/000050037. View

10.

Zlotnick A, Cheng N, Conway J, Booy F, Steven A, Stahl S . Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein. Biochemistry. 1996; 35(23):7412-21. DOI: 10.1021/bi9604800. View

11.

Studier F . Protein production by auto-induction in high density shaking cultures. Protein Expr Purif. 2005; 41(1):207-34. DOI: 10.1016/j.pep.2005.01.016. View

12.

Jeng K, Hu C, Chang C . Differential formation of disulfide linkages in the core antigen of extracellular and intracellular hepatitis B virus core particles. J Virol. 1991; 65(7):3924-7. PMC: 241430. DOI: 10.1128/JVI.65.7.3924-3927.1991. View

13.

Zlotnick A, Lee A, Bourne C, Johnson J, Domanico P, Stray S . In vitro screening for molecules that affect virus capsid assembly (and other protein association reactions). Nat Protoc. 2007; 2(3):490-8. PMC: 2099249. DOI: 10.1038/nprot.2007.60. View

14.

Li L, Liu J, Diao Z, Shu D, Guo P, Shen G . Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. Mol Biosyst. 2009; 5(11):1361-8. PMC: 2862387. DOI: 10.1039/b903428e. View

15.

Sorensen H, Mortensen K . Advanced genetic strategies for recombinant protein expression in Escherichia coli. J Biotechnol. 2004; 115(2):113-28. DOI: 10.1016/j.jbiotec.2004.08.004. View

16.

Palmer I, Wingfield P . Preparation and extraction of insoluble (inclusion-body) proteins from Escherichia coli. Curr Protoc Protein Sci. 2008; Chapter 6:6.3.1-6.3.18. PMC: 3518028. DOI: 10.1002/0471140864.ps0603s38. View

17.

Zlotnick A, Cheng N, Stahl S, Conway J, Steven A, Wingfield P . Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: implications for morphogenesis and organization of encapsidated RNA. Proc Natl Acad Sci U S A. 1997; 94(18):9556-61. PMC: 23216. DOI: 10.1073/pnas.94.18.9556. View

18.

Ramqvist T, Andreasson K, Dalianis T . Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther. 2007; 7(7):997-1007. DOI: 10.1517/14712598.7.7.997. View

19.

Choi K, Choi S, Jeon H, Kim I, Ahn H . Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. ACS Nano. 2011; 5(11):8690-9. DOI: 10.1021/nn202597c. View

20.

Hoption Cann S, van Netten J, van Netten C . Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2004; 79(938):672-80. PMC: 1742910. View